Brief: Rafael Pharmaceuticals - Phase 2 Clinical Trial Of CPI-613 Will Begin Enrolling Patients At Massachusetts General Hospital Starting December

Rafael Holdings

02/12/2019 14:23

Dec 2 (Reuters) - Rafael Holdings Inc  RFL.N :
    * RAFAEL PHARMACEUTICALS ANNOUNCES EXPANSION OF PHASE 2
TRIAL OF
CPI-613 (DEVIMISTAT) FOR PATIENTS WITH RELAPSED OR REFRACTORY
BURKITT’S LYMPHOMA/LEUKEMIA TO MASSACHUSETTS GENERAL HOSPITAL IN
BOSTON
    * RAFAEL HOLDINGS INC -  PHASE 2 CLINICAL TRIAL OF CPI-613
WILL
BEGIN ENROLLING PATIENTS AT MASSACHUSETTS GENERAL HOSPITAL IN
BOSTON STARTING DECEMBER

Source text for Eikon:  ID:nGNX9dvytq 
Further company coverage:  RFL.N 

 ((Reuters.Briefs@thomsonreuters.com;))